Cryoport (NASDAQ:CYRX) Upgraded to “Buy” at UBS Group

Cryoport (NASDAQ:CYRX) was upgraded by investment analysts at UBS Group from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a $10.00 price target on the stock. UBS Group’s price target points to a potential upside of 75.75% from the stock’s previous close.

Other analysts have also issued reports about the company. Guggenheim started coverage on Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Cryoport in a report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Cryoport Trading Down 1.4 %

Shares of CYRX stock opened at $5.69 on Monday. The company has a market cap of $283.99 million, a P/E ratio of -1.68 and a beta of 1.67. Cryoport has a fifty-two week low of $4.58 and a fifty-two week high of $20.11. The stock has a 50 day simple moving average of $6.81 and a two-hundred day simple moving average of $7.37. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport (NASDAQ:CYRX) last announced its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. During the same period in the previous year, the firm earned ($0.29) EPS. Research analysts forecast that Cryoport will post -0.99 earnings per share for the current year.

Insider Activity

In other news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 14,431 shares of company stock valued at $80,884. 10.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cryoport

A number of institutional investors have recently added to or reduced their stakes in CYRX. Franklin Resources Inc. boosted its holdings in Cryoport by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after acquiring an additional 1,512 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after purchasing an additional 1,764 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its position in Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after acquiring an additional 2,120 shares in the last quarter. Nebula Research & Development LLC raised its position in Cryoport by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after acquiring an additional 2,207 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Cryoport by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock valued at $3,144,000 after acquiring an additional 2,226 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.